It is thought that the selective inhibition of COX-2 by coxibs
results in a relative reduction in endothelial PGI2 synthesis, leaving platelet production of Tx[A.
Specifically in Colombia, where the availability of new COXIBs
in veterinary medicine is non-existent, as well as the variety of breeds and crossbreeds, makes the use of these specific COX2 inhibitors a new therapeutic alternative for canines with articular pain.
The theory underlying the development of the coxibs
was that selective COX-2 inhibition would provide analgesia and anti-inflammatory effects without the risks ofgastric bleeding associated with COX-1 inhibition.
Major Finding: Opioid users had higher rates of overall adverse events, severe adverse events, cardiovascular events, fractures, and all-cause mortality than did NSAID users or coxib
Bombardier C 2002 An evidence-based evaluation of the gastrointestinal safety of coxibs
American Journal of Cardiology 89 (6A) 3D-9D
Accordingly, as an initial test we evaluated this strategy with samples from a small study of coxib
use that prospectively identified cardiovascular adverse events (CV-AEs).
When co-morbidity factors are present, coxibs
should be used only as needed, and in doses lower than previously thought.
From a GI bleeding-risk perspective, a coxib
makes a better choice.
Their rate of hip, pelvis, wrist, or humerus fractures was 101 per 1,000 person-years, compared with 19 per 1,000 person-years in the coxib
group and 26 per 1,000 person-years in the NSAID group.
Or, similarly, for a new coxib
thought to be less harmful on the gastrointestinal tract than the best other remedy on the market, the scientific methodology would require enrollment of people who already have peptic ulcer disease.
En el texto tambien se abordan aspectos relacionados con el tratamiento de las enfermedades reumaticas, como tratamientos que en la actualidad son nuevas alternativas farmacologicas eficaces y seguras como los medicamentos llamados coxib
o inhibidores de COX-2, que alivian el dolor y la inflamacion.
4) Celecoxib, the prototype coxib
, was allowed to remain on the market in the United States.